remote possibilites

Texas punches in as one of best states for working from home, says study

More square footage and cost of internet are two big reasons Texas stands out. Photo by Maskot/Getty Images

The meaning of “going to work” is swiftly changing. The Ladders career platform forecasts that one-fourth of all professional jobs in North America will be remote by the end of 2022.

“This change in working arrangements is impossible to overhype. As big as it is, it’s even bigger than people think,” Marc Cenedella, CEO of The Ladders, said in December. “Hiring practices typically move at a glacial pace, but the pandemic turned up the heat so we’re seeing a rapid flood of change in this space. It’s really rather amazing.”

Given the dramatic shift in what it means to go to work, some folks with remote jobs may be wondering where they should live. It turns out that Texas sits at No. 7 on a new list from personal finance website WalletHub of the best states for working from home. So, if you hold a remote job and already call Texas home, you might just want to stay put.

To identify which places are best for working from home, WalletHub compared 12 key metrics for the 50 states and the District of Columbia. Those metrics include the cost of internet service and the size of a typical home. “Together, these metrics show how feasible working from home is in terms of cost, comfort, and safety,” WalletHub says.

Here’s how Texas fares in six categories, with a No. 1 position being best and a No. 25 position being average:

  • No. 1 for average square footage of homes.
  • No. 2 for cost of internet service.
  • No. 19 for share of potential telecommuters.
  • No. 25 for average price of electricity.
  • No. 25 for share of population working from home.
  • No. 29 for household internet access.

New Jersey grabs the No. 1 spot on the list, and Alaska ranks last.

“I believe that working from home will need to become a more viable option for many industries, regardless of the pandemic status, as we continue to see increasing fuel prices,” Sean Walker, professor of behavioral management in the College of Business and Global Affairs at the University of Tennessee at Martin, tells WalletHub.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted